Hone Health is a technology company.
Hone Health has raised $38.0M across 2 funding rounds.
Key people at Hone Health.
Hone Health has raised $38.0M in total across 2 funding rounds.
Key people at Hone Health.
Hone Health has raised $38.0M in total across 2 funding rounds.
Hone Health's investors include Alumni Ventures, Autopilot Fund, Builders, DNX Ventures, Elevate Ventures, Fifth Wall, Hawke Ventures, Hustle Fund, Magma Partners, Ravelin Capital, Redbud VC, Shaan's All Access Fund.
Hone Health is a telehealth company specializing in personalized hormone optimization and longevity care. It offers a comprehensive digital platform that includes advanced biomarker testing, telehealth consultations with licensed physicians, and home delivery of medications and supplements. The company primarily serves men and women seeking to improve energy, hormonal balance, weight management, sexual health, and overall longevity through data-driven, science-backed treatments. Hone Health’s approach addresses common age-related health issues such as low testosterone, weight loss challenges, and sexual dysfunction, delivering convenience and proactive care directly to consumers’ homes. The company has demonstrated strong growth momentum, recently raising $33 million in Series A funding and expanding its services to include home health offerings like IV therapy[1][2][3][4][6].
Founded in 2018 in New York City by Saad Alam, Hone Health emerged from Alam’s personal frustrations with the traditional healthcare system and his desire to create a more transparent, accessible, and effective approach to men’s and women’s health. The company initially focused on addressing hypogonadism (low testosterone) in men, a widespread but often underdiagnosed condition, before expanding into broader longevity and wellness categories such as weight loss, brain function, and sexual health. Early traction was driven by its personalized, data-driven care model and the convenience of telehealth, which resonated with a growing demographic of health-conscious individuals living in suburban and rural areas[1][3][4][5].
Hone Health rides the growing trend of personalized, preventive healthcare powered by telemedicine and biomarker-driven insights. The timing is favorable due to increasing consumer demand for convenient, data-backed health solutions and the rise of digital health platforms accelerated by the COVID-19 pandemic. Market forces such as an aging population, rising chronic disease prevalence, and greater health awareness support Hone’s mission. By integrating diagnostics, treatment, and home delivery in a unified platform, Hone Health is influencing the broader ecosystem by setting new standards for accessible, proactive longevity care and expanding the scope of telehealth beyond episodic treatment to continuous health optimization[1][3][4][6].
Looking ahead, Hone Health aims to scale its men’s and women’s health businesses significantly, targeting $100 million in recurring revenue while maintaining sustainable growth. The company plans to conduct clinical trials to validate its care model’s effectiveness, which could further establish its credibility and expand its market reach. Trends shaping its journey include advances in biomarker science, growing acceptance of hormone therapies, and increasing consumer preference for subscription-based, at-home healthcare services. Hone’s influence is likely to evolve as it broadens its service offerings and deepens patient engagement, potentially becoming a leading player in the longevity and preventive health space by combining technology, personalized medicine, and home health innovation[3][5].
This positions Hone Health as a pioneering telehealth clinic that empowers individuals to take control of their health and live longer, better lives through precision, convenience, and compassionate care.
Hone Health has raised $38.0M across 2 funding rounds. Most recently, it raised $33.0M Series A in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2025 | $33.0M Series A | Alumni Ventures, Autopilot Fund, Builders, DNX Ventures, Elevate Ventures, Fifth Wall, Hawke Ventures, Hustle Fund, Magma Partners, Ravelin Capital, Redbud VC, Shaan's All Access Fund, The General Partnership, Tribe Capital, Vine Ventures LP, Anthony Pompliano, Ben Davenport, Charlie Feng, Nik Sharma, Paul Rabil, Sam Parr | |
| Aug 1, 2020 | $5.0M Seed | B Capital Group, Incisive Ventures, Negev Capital, Pioneer Fund, Prithvi Ventures, Ravelin Capital, Satori Capital, What If Ventures, Rand Hindi |
